摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-氯甲基-5-[(3-(三氟甲基)苯基]-1,2,4-二唑 | 175205-63-7

中文名称
3-氯甲基-5-[(3-(三氟甲基)苯基]-1,2,4-二唑
中文别名
3-氯甲基-5-[(3-(三氟甲基)苯基]-1,2,4-噁二唑
英文名称
3-(chloromethyl)-5-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole
英文别名
3-(chloromethyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole;3-chloromethyl-5-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole;3-chloromethyl-5-(3-trifluoromethylphenyl)-[1,2,4]oxadiazole;3-chloromethyl-5-(3-trifluoromethyl)phenyl[1,2,4]oxadiazole
3-氯甲基-5-[(3-(三氟甲基)苯基]-1,2,4-二唑化学式
CAS
175205-63-7
化学式
C10H6ClF3N2O
mdl
MFCD00084969
分子量
262.619
InChiKey
INANILNLXTUPHD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    25-27°C
  • 沸点:
    322.5±52.0 °C(Predicted)
  • 密度:
    1.418±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    17
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    38.9
  • 氢给体数:
    0
  • 氢受体数:
    6

安全信息

  • 危险品标志:
    C
  • 安全说明:
    S26,S36/37/39,S45
  • 危险类别码:
    R34
  • 海关编码:
    2934999090

SDS

SDS:ac23dd1a22b1da9302d09b5b4bb21cdb
查看
Name: 3-(Chloromethyl)-5-[3-(trifluoromethyl)phenyl]-1 2 4-oxadiazole 95+% Material Safety Data Sheet
Synonym:
CAS: 175205-63-7
Section 1 - Chemical Product MSDS Name:3-(Chloromethyl)-5-[3-(trifluoromethyl)phenyl]-1 2 4-oxadiazole 95+% Material Safety Data Sheet
Synonym:

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
175205-63-7 3-(Chloromethyl)-5-[3-(trifluoromethyl 95+% unlisted
Hazard Symbols: C
Risk Phrases: 34

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 175205-63-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 25 - 27 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H6ClF3N2O
Molecular Weight: 263

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, bases.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide, fluorine, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 175205-63-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-(Chloromethyl)-5-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3261
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: III

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 175205-63-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 175205-63-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 175205-63-7 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A


上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-氯甲基-5-[(3-(三氟甲基)苯基]-1,2,4-二唑盐酸potassium carbonate 作用下, 以 乙醇N,N-二甲基甲酰胺 为溶剂, 生成 1,3-dipropyl-8-[1-({5-[3-(trifluoromethyl)phenyl](1,2,4-oxadiazol-3-yl)}methyl)pyrazol-4-yl]-1,3,7-trihydropurine-2,6-dione
    参考文献:
    名称:
    作为高亲和力和选择性A2B腺苷受体拮抗剂的新型1,3-二丙基-8-(1-杂芳基甲基-1H-吡唑-4-基)-黄嘌呤衍生物。
    摘要:
    合成了一系列新的1,3-二丙基-8-(1-杂芳基甲基-1H-吡唑-4-基)-黄嘌呤衍生物作为A(2B)-AdoR拮抗剂,并评估了它们与A(2B)的结合亲和力),A(1),A(2A)和A(3)-AdoR。8-(1-(((3-苯基-1,2,4-恶二唑-5-基)甲基)-1H-吡唑-4-基)-1,3-二丙基-1H-嘌呤-2,6( 3H,7H)-二酮(4)对A(2B)-AdoR与A(1),A(2A)和A(3)-AdoRs的亲和力(K(i)= 1 nM)和选择性高( A(1)/ A(2B),A(2A)/ A(2B)和A(3)/ A(2B)选择性比分别为370、1100和480)。本文介绍了这类新型化合物的合成和SAR。
    DOI:
    10.1016/j.bmcl.2005.10.002
  • 作为产物:
    参考文献:
    名称:
    The discovery of a selective, high affinity A2B adenosine receptor antagonist for the potential treatment of asthma
    摘要:
    Adenosine has been suggested to play a role in asthma, possibly via activation of A(2B) adenosine receptors on mast cells and other pulmonary cells. We describe our initial efforts to discover a xanthine based selective A(2B) AdoR antagonist that resulted in the discovery of CVT-5440, a high affinity A(2B) AdoR antagonist with good selectivity (A(2B) AdoR K-i = 50 nM, selectivity A(1) > 200: A(2A) > 200: A(3) > 167). (C) 2004 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2004.11.044
点击查看最新优质反应信息

文献信息

  • ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION
    申请人:Zablocki Jeff
    公开号:US20080032995A1
    公开(公告)日:2008-02-07
    Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.
    揭示了具有以下结构的新型异黄酮衍生物,其可用作ALDH-2抑制剂,用于治疗哺乳动物对成瘾药物的依赖,例如对多巴胺类药物如可卡因、吗啡、安非他命、尼古丁和酒精的依赖。
  • [EN] QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)<br/>[FR] DÉRIVÉS DE QUINUCLIDINE ET LEUR UTILISATION COMME ANTAGONISTES DES RÉCEPTEURS MUSCARINIQUES POUR LE TRAITEMENT DE L'ASTHME ET DE LA BRONCHOPNEUMOPATHIE CHRONIQUE OBSTRUCTIVE (BPCO)
    申请人:ASTRAZENECA AB
    公开号:WO2009139709A1
    公开(公告)日:2009-11-19
    The invention provides compounds of formula (I) wherein R1, R2, R3, R4, R5, Het1, n, Y and X are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them, a process for preparing pharmaceutical compositions, their use in therapy and intermediates of use in their preparation.
    本发明提供式(I)化合物,其中R1、R2、R3、R4、R5、Het1、n、Y和X如说明书中所定义,制备这些化合物的方法,含有这些化合物的药物组合物,制备药物组合物的方法,它们在治疗中的用途,以及用于制备它们的中间体。
  • ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS
    申请人:Diamond Ivan
    公开号:US20090124672A1
    公开(公告)日:2009-05-14
    Disclosed are isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for use treating in mammals suffering from psychiatric disorders such as, for example, depression, generalized anxiety, social phobia, panic disorder, and sleep disorders.
    披露的是具有公式I结构的异黄酮衍生物,它们作为ALDH-2抑制剂,用于治疗遭受精神疾病困扰的哺乳动物,例如抑郁症、广泛性焦虑症、社交恐惧症、恐慌症和睡眠障碍。
  • Substituted phenyl farnesyltransferase inhibitors
    申请人:——
    公开号:US20020019527A1
    公开(公告)日:2002-02-14
    Compounds of formula (I) 1 or pharmaceutically acceptable salts thereof, inhibit farnesyltransferase. Methods for making the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds are disclosed.
    式(I)的化合物或其药学上可接受的盐,抑制法尼基转移酶。公开了制备这些化合物的方法,含有这些化合物的药物组合物,以及使用这些化合物进行治疗的方法。
  • [EN] ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION<br/>[FR] INHIBITEURS D'ALDH-2 DANS LE TRAITEMENT D'UNE ACCOUTUMANCE
    申请人:CV THERAPEUTICS INC
    公开号:WO2009094028A1
    公开(公告)日:2009-07-30
    Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.
    揭示了具有Formula I结构的新型异黄酮衍生物,可用作ALDH-2抑制剂,用于治疗哺乳动物对成瘾药物的依赖,例如对多巴胺类药物如可卡因、吗啡、安非他命、尼古丁和酒精的依赖。
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺